Envestnet Asset Management
RVNC

Envestnet Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Envestnet Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,149
Closed -$220K – 4192
2023
Q3 		$220K Sell
19,149
-6,353
-25% -$122K ﹤0.01% 3700
2023
Q2 		$645K Buy
25,502
+6,129
+32% +$191K ﹤0.01% 3064
2023
Q1 		$624K Sell
19,373
-9,446
-33% -$294K ﹤0.01% 3002
2022
Q4 		$532K Buy
28,819
+14,509
+101% +$332K ﹤0.01% 3064
2022
Q3 		$386K Buy
14,310
+3,642
+34% +$73.9K ﹤0.01% 3197
2022
Q2 		$147K Sell
10,668
-1,875
-15% -$28.9K ﹤0.01% 3700
2022
Q1 		$245K Sell
12,543
-7,751
-38% -$118K ﹤0.01% 3564
2021
Q4 		$331K Sell
20,294
-15,197
-43% -$253K ﹤0.01% 3352
2021
Q3 		$989K Buy
35,491
+558
+2% +$15.9K ﹤0.01% 2553
2021
Q2 		$1.03M Buy
34,933
+22,853
+189% +$659K ﹤0.01% 2502
2021
Q1 		$338K Buy
12,080
+2,497
+26% +$69.1K ﹤0.01% 3074
2020
Q4 		$272K Sell
9,583
-1,230
-11% -$31.9K ﹤0.01% 2972
2020
Q3 		$272K Buy
10,813
+357
+3% +$9.36K ﹤0.01% 2778
2020
Q2 		$255K Sell
10,456
-372
-3% -$7.34K ﹤0.01% 2762
2020
Q1 		$160K Sell
10,828
-1,434
-12% -$29.7K ﹤0.01% 2773
2019
Q4 		$199K Buy
+12,262
New +$190K ﹤0.01% 2924
2017
Q3 		– Sell
-27
Closed -$1K – 3064
2017
Q2 		$1K Hold
27
– – ﹤0.01% 3012
2017
Q1 		$1K Hold
27
– – ﹤0.01% 3076
2016
Q4 		$1K Buy
+27
New +$452 ﹤0.01% 3058

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Envestnet Asset Management's RVNC Position: Q4 2023 in Review

Envestnet Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 19,149 shares — an estimated $220K sold.

Envestnet Asset Management first reported a position in RVNC in Q4 2016 and held it in 19 quarters. The position peaked at $1.03M in Q2 2021. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

  • Envestnet Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Envestnet Asset Management sold 19,149 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $220K.
  • Envestnet Asset Management first reported a position in Revance Therapeutics, Inc. in Q4 2016 and held it in 19 quarters.
  • Envestnet Asset Management's Revance Therapeutics, Inc. position peaked at $1.03M in Q2 2021.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Envestnet Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.